

comparison differs significantly from the setting described in the study protocol.

Aaron *et al* advocate that any intention to treat analysis is superior to other strategies. However, when withdrawal rates are substantial, as in the Optimal Trial, and patients withdrawing from study medication are given medication being tested in the trial, any conclusion on analysis methodology should be made with caution.

J Vestbo

North West Lung Centre, Wythenshawe Hospital, Manchester, UK; and Department of Cardiology and Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark

Correspondence to: Dr J Vestbo, 2nd Floor ERC Building, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK; jorgen.vestbo@manchester.ac.uk

Competing interests: JV has been involved in clinical trials of inhaled corticosteroid alone or in combination with long acting beta agonists; his wife is an employee of AstraZeneca.

REFERENCES

1. Aaron SD, Fergusson D, Marks GB, *et al*. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. *Thorax* 2008;**63**:122–8
2. Aaron SD, Vandemheen K, Fergusson D, *et al*. Tiotropium in combination with placebo, salmeterol, or fluticasone/salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2007;**146**:545–55.

Author's reply

We would like to thank Dr Vestbo for his comments. We agree that in the Optimal Trial more patients originally randomised to the placebo arm prematurely discontinued study medications, and that many of these patients were subsequently put on open label ICS/LABA products.¹ As discussed in our paper, the relative risk reduction decreased from 21% if patients were prematurely excluded once they discontinued study drugs to 15% when an intent to treat analysis was used.² We agree with Dr Vestbo that our intention to treat analysis was conservative, and it did slightly reduce the possibility of a difference being found between placebo and active treatment but we would argue that this analysis was necessary in order to prevent bias.

An intention to treat analysis is necessary as it is impossible to know a priori the ultimate direction of the bias when patients who stop study medications early are banished from a clinical trial. Will the bias favour the drug or favour placebo? For example, a similar analysis of a trial assessing tiotropium for chronic obstructive pulmonary disease (COPD)³ showed that the bias can work exactly in the opposite direction and instead favour placebo over active drug. In this study, higher incidence rates of fatal events occurred following premature discontinuation of study medication, especially in those patients randomised to the placebo arm.

Presumably, patients who were taking placebo in this study were doing poorly and many prematurely stopped study drugs and then, shortly thereafter, they died. In this case, early exclusion of these patients would have introduced bias because the factors which determined whether a patient might have been excluded were also related to the outcome. If these patients had been dropped from the trial after premature discontinuation of study medications, this would have meant that their deaths would not have been discovered, and this would have produced a biased mortality incidence ratio in favour of placebo over tiotropium. The authors of this study concluded that failure to consider outcomes of patients who discontinue study medications early may bias results against effective therapies.⁴ Only by ensuring full follow-up of all randomised patients and by using a proper intention to treat analysis was this potential bias eliminated.

There is an old saying in medicine “You can't find a fever if you don't take a temperature”. This applies to clinical trials as well; the investigator cannot know what really happened in a clinical trial unless he/she evaluates outcomes in all randomised patients for the full study follow-up period, regardless of patient compliance.

S D Aaron

Correspondence to: Dr S D Aaron, The Ottawa Hospital/Ottawa Health Research Institute, General Campus 501, Smyth Road Mailbox #211, Ottawa, Canada K1H 8L6; saaron@ohri.ca

Competing interests: None.

REFERENCES

1. Aaron SD, Vandemheen K, Fergusson D, *et al*. Tiotropium in combination with placebo, salmeterol, or fluticasone/salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. *Ann Intern Med* 2007;**146**:545–55.
2. Aaron SD, Fergusson D, Marks GB, *et al*. Counting, analyzing and reporting exacerbations of COPD in randomised controlled trials. *Thorax* 2008;**63**:122–8.
3. Niewoehner DE, Rice KL, Cote CG, *et al*. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. a randomized trial. *Ann Intern Med* 2005;**143**:317–26.
4. Kesten S, Plautz M, Piquette C, *et al*. Premature discontinuation of patients: a potential bias in COPD clinical trials. *Eur Respir J* 2007;**30**:898–906.

IL1 may be elevated but is it all bad in ARDS?

Frank *et al* have elegantly demonstrated in animal models of ventilator associated lung injury (VALI) that interleukin 1 β (IL1 β) may play a role in the development of alveolar barrier dysfunction. However, the ventilation strategy used for these experiments (with a very high tidal volume of 30 ml/kg) induced an increase in IL1 β of only 36 pg/ml in lavage as opposed to 7 pg/ml in their control animals, a level that in their *in vitro* models

of epithelial resistance and permeability did not significantly affect permeability.¹

Our recent study published in *Thorax* has evaluated IL1 β levels in bronchoalveolar lavage fluid in patients with adult respiratory distress syndrome (ARDS) as 143 pg/ml.² Thus their animal model does not adequately reflect the *in vivo* situation in patients with established ARDS. We believe this may be important because several lines of evidence suggest that IL1 β may play a role in stimulating repair of the alveolar epithelium.

Effective alveolar repair following the development of ARDS is believed to involve the transdifferentiation of alveolar type II cells (ATII), which retain stem cell-like properties, into type I cells via intermediate cell phenotypes. The turnover rate of ATII cells is boosted after acute lung injury and the recovery process is believed to involve cell migration and proliferation in addition to transdifferentiation of ATII epithelial cells.³

Geiser *et al* were the first to show that pulmonary oedema fluid, early in the course of ARDS, stimulates repair of wounded monolayers in culture to a greater extent than plasma obtained from the same patients or pulmonary oedema fluid from patients with hydrostatic oedema.⁴ The potential of oedema fluid to promote wound repair was associated with a trend towards improved survival and reduction in the duration of ventilation. The enhanced wound repair is IL1 β dependent and mediated by autocrine release of epidermal growth factor and transforming growth factor α .⁵ Recently, we have further demonstrated that lung lavage fluid from ARDS patients treated with intravenous salbutamol enhanced A549 monolayer wound repair responses compared with placebo treated patients *in vitro* by an IL1 β dependent mechanism.²

In conclusion, the data from the study by Frank *et al* clearly demonstrate that increased IL1 signalling may be an early mechanism of alveolar barrier dysfunction in VALI in rats and mice. However, significant evidence suggests that once ARDS is established, elevated IL1 levels may have beneficial effects on epithelial repair. We believe that this may therefore account for the apparent failure of anti-IL1 strategies in humans with ARDS.

D R Thickett, G D Perkins

University of Birmingham, Birmingham, UK

Correspondence to: Dr D R Thickett, Lung Investigation Unit, 1st Floor, Nuffield House, Queen Elizabeth Hospital, Birmingham B15 2TH, UK; d.thickett@bham.ac.uk

Competing interests: None.

REFERENCES

1. Frank JA, Pittet JF, Wray C, *et al*. Protection from experimental ventilator-induced acute lung injury by IL1 receptor blockade. *Thorax* 2008;**63**:147–53.
2. Perkins GD, Gao F, Thickett DR. *In vivo* and *in vitro* effects of salbutamol upon alveolar epithelial repair in acute lung injury. *Thorax* 2008;**63**:215–20.

3. **Berthiaume Y**, Lesur O, Dagenais A. Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium. *Thorax* 1999;**54**:150–60.
4. **Geiser T**, Atabai K, Jarreau PH, *et al*. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. *Am J Respir Crit Care Med* 2001;**163**:1384–8.
5. **Geiser T**, Jarreau PH, Atabai K, *et al*. Interleukin-1beta augments in vitro alveolar epithelial repair. *Am J Physiol Lung Cell Mol Physiol* 2000;**279**:L1184–90.

Authors' reply

We appreciate the comments from Drs Thickett and Perkins and welcome the opportunity to further discuss the potential roles of interleukin 1 (IL1) in the pathogenesis and repair of acute lung injury.

Regarding the differences in IL1 β levels in bronchoalveolar lavage fluid (BALF) obtained from mice and humans, we do not believe that the differences are surprising. IL1 β levels are influenced by the lavage volume and the specific assays used. The primary finding is that IL1 β mRNA expression and protein levels are markedly increased in the lung early in the course of ventilator induced lung injury.

We agree that the potential broader role of IL1 in alveolar repair and lung fibrosis should be considered when designing future studies of IL1 blockade for acute lung injury. Because of space limitations, we could not elaborate on this important issue in our manuscript.¹ Previous clinical studies have reported that the majority of the pro-inflammatory activity in BALF is attributable to IL1.² Through both neutrophil recruitment and an effect of epithelial cells, IL1 induces an increase in permeability to protein.¹ IL1 β also downregulates epithelial sodium channel (ENaC) expression and impairs vectorial fluid transport.³ Together, these effects favour pulmonary oedema formation, the hallmark of acute lung injury and ARDS. Although we have found that IL1 impairs alveolar barrier permeability, previous work from our group has demonstrated that IL1 promotes alveolar epithelial cell migration.^{4,5} It is conceivable that blocking IL1 signalling could interfere with normal alveolar epithelial cell migration over the basement membrane during the repair phase of acute lung injury. However, one recent study found that mesenchymal stem cells prevented both acute lung injury and fibrosis following bleomycin administration in mice. The effect was attributable to IL1 receptor antagonist expression in the stem cells.⁶ Additionally, chronic overexpression of IL1 β induces acute lung injury followed by pulmonary fibrosis,⁷ although the mechanisms for the acute inflammatory response and later fibrosis may be distinct.⁸ Together these data show that IL1 signalling may govern a broad spectrum of inflammatory and repair processes in the injured lung. Differences in the timing of IL1 blockade may have different effects on injury and repair. Our hypothesis is

that early blockade of IL1 signalling may limit the quantity of pulmonary oedema by preserving barrier function and sodium transport, while later IL1 blockade may affect epithelial repair and fibrosis. Additional studies of transgenic mice and IL1 receptor antagonist in other models of acute lung injury and fibrosis may shed more light on how the timing of IL1 signalling during lung injury influences the diverse effects of this cytokine.

Previous clinical trials have not directly addressed the question of the efficacy of IL1 receptor antagonist in patients with acute lung injury. Given the lack of effective therapies for this syndrome of acute respiratory failure in critically ill patients, we believe that further investigation of IL1 receptor antagonist is warranted.

J A Frank, J Francois-Pittet, M A Matthey

University of California, San Francisco, California, USA

Correspondence to: Dr J A Frank, University of California, San Francisco, 4150 Clement Street, Box 111D, San Francisco, CA 94121, USA; james.frank@ucsf.edu

Competing interests: None.

REFERENCES

1. **Frank JA**, Pittet JF, Wray C, *et al*. Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade. *Thorax* 2008;**63**:147–53.
2. **Pugin J**, Ricou B, Steinberg KP, *et al*. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. *Am J Respir Crit Care Med* 1996;**153**:1850–6.
3. **Roux J**, Kawakatsu H, Gartland B, *et al*. Interleukin-1beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway. *J Biol Chem* 2005;**280**:18579–89.
4. **Geiser T**, Jarreau PH, Atabai K, *et al*. Interleukin-1beta augments in vitro alveolar epithelial repair. *Am J Physiol Lung Cell Mol Physiol* 2000;**279**:L1184–90.
5. **Geiser T**, Atabai K, Jarreau PH, *et al*. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. *Am J Respir Crit Care Med* 2001;**163**:1384–8.
6. **Ortiz LA**, Dutreil M, Fattman C, *et al*. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci U S A* 2007;**104**:11002–7.
7. **Kolb M**, Margetts PJ, Anthony DC, *et al*. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. *J Clin Invest* 2001;**107**:1529–36.
8. **Bonniaud P**, Margetts PJ, Ask K, *et al*. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. *J Immunol* 2005 Oct 15;**175**:5390–5.

Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field

The study by Aubin *et al*¹ published in this issue is significant in that it is the first head-to-head comparison of the two smoking cessation pharmacotherapies: varenicline and nicotine replacement therapy (NRT). The results suggest that varenicline yielded higher rates of smoking abstinence than NRT. However, an important flaw in the

design hampers the interpretation of the results. An imbalance resulted from the fact that the varenicline group began treatment 1 week before the target quit date whereas the NRT group began treatment on the quit date. Although the authors justified this decision based on current manufacturer's instructions for using NRT, the asymmetrical design is problematic.

The problem with the imbalanced design stems from the finding that initiating NRT before the quit date approximately doubles the efficacy of NRT compared with beginning treatment on the quit date.² It is plausible that a similar enhancement of efficacy results from initiating varenicline before the quit date. Therefore, beginning varenicline but not NRT before the quit date may have created an unfair advantage for varenicline. Although most studies of pre-cessation NRT have used pretreatment for 2 weeks as opposed to 1 week, it is conceivable that even pre-cessation exposure to treatment for 1 week augments success rates.

A likely mechanism for the enhancement in efficacy with pre-cessation treatment is behavioural extinction.³ Extinction results from a reduction in the rewarding effects of cigarettes when they are smoked concurrently with NRT or with a nicotinic antagonist such as mecamylamine,⁴ or with the nicotinic receptor partial agonist varenicline.⁵ This decrement in smoking reward may, in turn, reduce dependence levels and facilitate quitting smoking.

Pre-cessation NRT is not approved by the Food and Drugs Administration, but this recommendation may change as more studies replicate the positive results with pre-cessation NRT.⁶ Moreover, the main concern expressed regarding smoking concurrently with NRT—nicotine overdose—can be obviated by switching patients to denicotinised cigarettes during pre-cessation treatment with NRT.⁴

A comparison of NRT and varenicline using equal pre-cessation treatment regimens will ultimately prove informative in evaluating these two treatments.

J E Rose

Correspondence to: Professor J E Rose, Department of Psychiatry and Behavioral Sciences, Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, 2424 Erwin Road, Suite 201, Durham, NC 27705, USA; rose0003@mc.duke.edu

Competing interests: The author is a named inventor on several nicotine replacement patents.

REFERENCES

1. **Aubin H-J**, Bobak A, Britton JR, *et al*. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax* 2008;**63**:717–24.
2. **Shiffman S**, Ferguson SG. Nicotine patch therapy prior to quitting: a meta-analysis. *Addiction* 2008;**103**:557–63.
3. **Donny EC**, Houtsmuller E, Stitzer ML. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. *Addiction* 2007;**102**:324–34.
4. **Rose JE**, Behm FM. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. *Nicotine Tob Res* 2004;**6**:523–32.